In: NEOPLASMA, vol. 53, no. 2
L. Elbl - I. Vasova - I. Tomaskova - F. Jedlicka - M. Navratil - Z. Pospisil - J. Vorlicek
Detaily:
Rok, strany: 2006, 174 - 181
O článku:
Authors conducted a one-year prospective study to determine
whether CHOP regimen (cyclophosphamide, doxorubicin,
vincristin, and prednisone), used in the treatment of aggressive
non-Hodgkin´s lymphoma, is associated with the presence of
an early impairment of cardiac function. Forty seven patients were
prospectively examined (27 male and 20 female) aged
49+/-14 years who were treated with CHOP regimen. Rest
echocardiography was performed at baseline and one-year control.
Cardiopulmonary exercise test was carried out at one-year control
examination. The ejection fraction (EF), parameters of diastolic
function, myocardial performance index (MPI), and pVO2 were used
as parameters of cardiopulmonary performance.
The cumulative dose (CD) of doxorubicin was 277+/-56 (300 mg/m2) was
given. The baseline EF 64+/-5% (64%) decreased
to 58+/-7% (57%) at the one-year control (p<0.0001). 23% of patients
exhibited a drop in EF >10% during the
follow-up. 43% revealed a pathologically increased value of MPI
>0.55, and 47% impaired diastolic function compared to
the baseline values, respectively. 21% of patients exhibited a
decrease of pVO2 <20 ml/kg/min, and 17% pVO2<80% of the
reference value, respectively. None of the patients developed
signs of heart failure. The Doppler parameters of both diastolic
and global LV function were the most affected measures and
significantly influenced the cardiopulmonary performance.
Multivariate analysis showed that CD ⩾300 mg/m2 (OR=8.08; p<0.05)
and the presence of risk factors (OR=9.48; p<0.008)
are the best predictors of cardiotoxicity.
The results show that subclinical cardiac impairment was frequent
in patients receiving the CHOP regimen with safe cumulative
doses of doxorubicin. The value of described changes for the
development of heart failure has to be assessed during
the prospective follow-up.
Ako citovať:
ISO 690:
Elbl, L., Vasova, I., Tomaskova, I., Jedlicka, F., Navratil, M., Pospisil, Z., Vorlicek, J. 2006. Cardiac function and cardiopulmonary performance in patients after
treatment for non-Hodgkin´s lymphoma. In NEOPLASMA, vol. 53, no.2, pp. 174-181. 0028-2685.
APA:
Elbl, L., Vasova, I., Tomaskova, I., Jedlicka, F., Navratil, M., Pospisil, Z., Vorlicek, J. (2006). Cardiac function and cardiopulmonary performance in patients after
treatment for non-Hodgkin´s lymphoma. NEOPLASMA, 53(2), 174-181. 0028-2685.